Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

Table 3

Multivariable Cox regression analysis of the prognosis of the patients treated with gemcitabine.

Clinicopathologic variable	N = 31	Median DFS (months)	HR	95% CI	value
Tumour type
Adenocarcinoma	21	14.00	0.895	0.344–2.327	0.819
Squamous cell carcinoma	10	16.00
Stage
I	12	16.00			0.281
II	7	16.00	0.508	0.188–1.377	0.183
III	12	11.00	0.459	0.149–1.420	0.177
Age, years
>52	14	14.00	0.861	0.359–2.065	0.738
≤52	17	16.00
Sex
Female	5	20.00	1.518	0.364–6.340	0.567
Male	26	14.00
Whether to detect the expression of three genes
Yes	19	17.00	0.324	0.121–0.870	0.025
No	12	10.00